News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

APOXIS S.A. Receives FDA Orphan Medicinal Product Designation For APO200 For The Treatment Of XLHED


2/2/2006 2:20:26 PM

Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has received Orphan Medicinal Product designation from the FDA for its rare disease protein therapeutic, APO200.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES